{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:43:36Z","timestamp":1759405416341,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2021.12.070","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T21:28:37Z","timestamp":1641936517000},"page":"1026-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System"],"prefix":"10.1016","volume":"40","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.12.070_b0005","unstructured":"Fluzone High-Dose Quadrivalent approval letter. https:\/\/www.fda.gov\/media\/132239\/download"},{"key":"10.1016\/j.vaccine.2021.12.070_b0010","unstructured":"Fluzone High-Dose Quadrivalent package insert. https:\/\/www.fda.gov\/media\/132238\/download"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.070_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021\u201322 Influenza Season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"36","key":"10.1016\/j.vaccine.2021.12.070_b0020","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.070_b0025","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2021.12.070_b0030","unstructured":"Code of Federal Regulations. 21 600.80."},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2021.12.070_b0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"issue":"31","key":"10.1016\/j.vaccine.2021.12.070_b0040","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.070_b0045","doi-asserted-by":"crossref","unstructured":"DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. Proceeding of the conference on knowledge discovery and data; 2001 Aug 26-29; San Diego (CA): ACM Press 67-76.","DOI":"10.1145\/502512.502526"},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.070_b0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s Spontaneous Reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"43","key":"10.1016\/j.vaccine.2021.12.070_b0055","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.vaccine.2019.08.045","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after 2015\u20132016 and 2016\u20132017 influenza vaccination of Medicare beneficiaries","volume":"37","author":"Arya","year":"2019","journal-title":"Vaccine."},{"issue":"24","key":"10.1016\/j.vaccine.2021.12.070_b0060","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med."},{"issue":"18","key":"10.1016\/j.vaccine.2021.12.070_b0065","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barre syndrome","volume":"80","author":"van den Berg","year":"2013","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.070_b0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1212\/WNL.52.3.635","article-title":"Fatal Guillain-Barr\u00e9 syndrome","volume":"52","author":"Lawn","year":"1999","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.vaccine.2021.12.070_b0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2021.12.070_b0080","unstructured":"IOM (Institute of Medicine). Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press; 2011."},{"key":"10.1016\/j.vaccine.2021.12.070_b0085","doi-asserted-by":"crossref","unstructured":"Perez-Vilar S, Hu M, Weintraub E, Arya D, Lufkin B, Myers T, et al. Guillain-Barr\u00e9 Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season. J Infect Dis. 2021 Feb 13; 223(3): 416\u2013425.","DOI":"10.1093\/infdis\/jiaa543"},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.070_b0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in US infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2021.12.070_b0095","unstructured":"FDA Biologics Effectiveness and Safety System https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system; accessed 12\/17\/2021"},{"key":"10.1016\/j.vaccine.2021.12.070_b0100","unstructured":"Centers for Medicare & Medicaid Services. Medicare program \u2013 general information https:\/\/www.cms.gov\/medicare\/medicare-general-information\/medicaregeninfo; accessed 12\/17\/2021"},{"key":"10.1016\/j.vaccine.2021.12.070_b0105","unstructured":"Vaccine Safety Datalink https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html; accessed 12\/17\/2021"},{"key":"10.1016\/j.vaccine.2021.12.070_b0110","unstructured":"About The Vaccine Adverse Event Reporting System (VAERS) https:\/\/wonder.cdc.gov\/vaers.html; accessed 12\/17\/2021"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:27Z","timestamp":1759403247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000019"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}